OmniAb, Inc.
OABIOmniAb is a biotechnology company that provides a technologically advanced antibody discovery platform to pharmaceutical and biotech partners.
Earnings
Next report
Date not yet announcedCompetitors
By market cap
By revenue growth
Profile
OmniAb is a biotechnology company that provides a technologically advanced antibody discovery platform to pharmaceutical and biotech partners. The company leverages its proprietary Biological Intelligence, powered by engineered transgenic animals and AI-driven screening tools, to identify high-quality therapeutic antibody candidates. Its business model is centered on licensing these technologies to enable the discovery of next-generation therapeutics for a wide range of human diseases.
OmniAb is a leading provider of multi-species transgenic animal platforms, uniquely offering rat, mouse, and chicken technologies for antibody discovery.
FAQ
- What is OmniAb, Inc.'s market cap?
- OmniAb, Inc. (OABI) has a market capitalization of $760.4M and trades on NASDAQ.
- Who are OmniAb, Inc.'s competitors?
- OmniAb, Inc.'s key competitors include AbCellera Biologics Inc., Twist Bioscience Corporation, Bruker Corporation, and others. These companies compete in similar markets and product categories.
- Who does OmniAb, Inc. partner with?
- OmniAb, Inc.'s notable partners include mAbsolve Ltd., Stanford University, The Scripps Research Institute, and others.
- What subsidiaries does OmniAb, Inc. have?
- OmniAb, Inc.'s subsidiaries include Open Monoclonal Technology, Inc., Crystal Bioscience, Inc., Ab Initio Biotherapeutics, Inc., and others.
- Where is OmniAb, Inc. headquartered?
- OmniAb, Inc. is headquartered in United States of America and employs approximately 106 people. It has been publicly traded since 2022.